A região N-terminal de OTI-VIT-1 foi expressa e os polipeptídeos recombinantes foram purificados. OTI-VIT-1 pode ser homólogo da vitelina YP170B de C. elegans. Foram identificados um intron na região 5´ e dois na região 3´ do gene Oti-vit-1. Antissoro monoespecífico para PVIT1HisC confirmou que o gene Oti-vit-1 codifica VT1. O polipeptídeo recombinante P40-H, correspondente à região N-terminal da proteína OTI-VIT-6 interage com um polipeptídeo de aproximadamente 100 kDa (P100) presente em extratos proteicos totais de O. tipulae. Estudamos também o papel da Proteína Microssômica Transportadora de Triglicerídeos (MTP) na biossíntese de Vitelogenina do nematoide C. elegans. Ensaios de RNAi em C. elegans, utilizando parte da sequência do gene da MTP (Cel-dsc-4) foram realizados nas linhagens N2 e DH1033. Microscopia de fluorescência de vermes adultos da linhagem DH1033, submetidos a RNAi, mostrou acúmulo de YP170B::GFP no interior dos enterócitos. Este acúmulo sugere a participação da MTP na secreção de VTG. Análise imunológica da vitelogenina nestes mesmos vermes não detectaram alterações no processamento de CEL-VIT-6, sugerindo que o mesmo ocorra não só no pseudoceloma, mas também no interior dos enterócitos. / The N-terminal region of OTI-VIT-1 was expressed and the recombinant polypeptides were purified. OTI-VIT-1 may be homologous to the vitellin YP170B from C. elegans. We identified an intron in the 5 \'region and two in 3\' region from Oti-vit-1. Monospecific antisera to PVIT1HisC confirmed that the gene Oti-vit-1 encodes VT1. The recombinant polypeptide P40-H, corresponding to the N-terminal region of the protein OTI-VIT-6, interacts with a polypeptide of approximately 100 kDa (P100) present in total protein extracts of O. tipulae. The role of microsomal triglyceride transfer protein (MTP) in the biosynthesis of vitellogenin was studied in the nematode C. elegans. Trials of RNAi in C. elegans, using the sequence of the MTP gene (Cel-dsc-4) were performed in the strains N2 and DH1033. Fluorescence microscopy of adult worms of strain DH1033, subjected to RNAi, showed accumulation of YP170B:: GFP within the enterocytes. This accumulation suggests the involvement of MTP in the secretion of VTG. Analysis using anti-vitellogenin immune serum did not detect changes in the processing of CEL-VIT-6, suggesting that it occurs not only in pseudocoelom but also within the enterocytes.

<p>There is convincing research which shows that the enzyme alkaline phosphatase (ALP) has a central role in the mineralization of bone, more precisely that its catalytic activity is needed in the process. ALP is found on the surface of matrix vesicles where the mineral is formed. One theory about the function of the enzyme is that it binds to fibrous collagen in the bone and thereby incorporating the mineral into the bone. The purpose of this study is to establish whether ALP binds to collagen. If this is the case, more elaborate studies around this will be performed. The strength of the binding between collagen and the different types of ALP will be evaluated, as well as on which part of the collagen the binding occurs. The binding is going to be studied by constructing a method for the ÄKTApurifier system.</p><p> </p><p>Initially, the pureness of the different type of collagens was determined by using SDS-PAGE and the activity of the different types of ALP was established. These were also compared with a native PAGE. In SDS-PAGE, bovine type I collagen showed markings for a triple helix, a double helix and two single strains, α₁ and α₂. Bovine type II collagen showed markings for a double helix and α₁-strains. Human type I collagen showed markings for a triple helix, two double helixes, two α-strains and contaminations. Trials with collagen in Native PAGE did not provide any results. However, the trials with ALP revealed that the different types of ALP had different charge.</p><p> </p><p>Thereafter, blotting was performed. The results showed that all the different types of ALP, besides from E. coli, binds to bovine collagen type I and II and human collagen type I, however within various periods of time. In the trials with collagen coated plates the acquired results showed that some of the different types of ALP bind to collagen. ALP from liver binds the strongest to both collagen type I from rat and type IV from mouse. Intestinal ALP also binds to both types of collagen but not nearly as strong as liver ALP. Serum from rats did bind to collagen type I from rat but not to collagen type IV from mouse. ALP from kidney and human serum did not bind to either types of collagen. The trials concerning the ÄKTApurifier system were executed with ALP from liver alone because it had been proven to bind to bovine type I collagen through the previous methods. The results confirmed that ALP from liver binds to this type of collagen.</p><p> </p><p>The conclusions from this study are that ALP does indeed bind to collagen and does so to the triple helix and double helix form as well as the single strains of collagen. In other words the part of the structure in collagen that ALP binds to must exist in all three stages of collagen formation. Furthermore, it seems like some of the different types of ALP has a higher affinity for binding to collagen, as the time for binding to collagen varies for the different types of ALP. The results differed between methods concerning different types of ALP. Although, the method we consider to give the best result was blotting. However, the method using ÄKTApurifier can be complementary but needs further development.</p>

<p>Nuts of all kinds are common ingredients in food. For nut allergy sufferers the frequent use of nuts cause problems and "hidden" nuts in food products may elicit allergic reaction when such foods are consumed. Methods for detecting and quantifying walnut (and other nuts) with high sensitivity and specificity are therefore very important.</p><p>The objective of this project was to verify the specificity of a rabbit antiserum against walnut with immunodiffusion and to determine the size of the dominant walnut antigens with Western blotting. In addition, a commercial sandwich ELISA for walnut quantification was validated and compared with a qualitative real-time PCR.</p><p>The rabbit antiserum proved to be less specific but after absorption with cross-reacting nuts and seeds it showed high specificity. The ELISA kit reacted, except for walnut, with pecan and slightly with other nuts and seeds tested. The PCR showed an absolute specificity to walnut. As low levels as 2.5mg walnut/kg can be quantified with the ELISA. This is 8 to 100 fold less than with the PCR method. It is therefore concluded that the ELISA kit is more sensitive than the PCR method but the PCR method is more specific than the ELISA kit.</p>

Nuts of all kinds are common ingredients in food. For nut allergy sufferers the frequent use of nuts cause problems and "hidden" nuts in food products may elicit allergic reaction when such foods are consumed. Methods for detecting and quantifying walnut (and other nuts) with high sensitivity and specificity are therefore very important. The objective of this project was to verify the specificity of a rabbit antiserum against walnut with immunodiffusion and to determine the size of the dominant walnut antigens with Western blotting. In addition, a commercial sandwich ELISA for walnut quantification was validated and compared with a qualitative real-time PCR. The rabbit antiserum proved to be less specific but after absorption with cross-reacting nuts and seeds it showed high specificity. The ELISA kit reacted, except for walnut, with pecan and slightly with other nuts and seeds tested. The PCR showed an absolute specificity to walnut. As low levels as 2.5mg walnut/kg can be quantified with the ELISA. This is 8 to 100 fold less than with the PCR method. It is therefore concluded that the ELISA kit is more sensitive than the PCR method but the PCR method is more specific than the ELISA kit.

There is convincing research which shows that the enzyme alkaline phosphatase (ALP) has a central role in the mineralization of bone, more precisely that its catalytic activity is needed in the process. ALP is found on the surface of matrix vesicles where the mineral is formed. One theory about the function of the enzyme is that it binds to fibrous collagen in the bone and thereby incorporating the mineral into the bone. The purpose of this study is to establish whether ALP binds to collagen. If this is the case, more elaborate studies around this will be performed. The strength of the binding between collagen and the different types of ALP will be evaluated, as well as on which part of the collagen the binding occurs. The binding is going to be studied by constructing a method for the ÄKTApurifier system.   Initially, the pureness of the different type of collagens was determined by using SDS-PAGE and the activity of the different types of ALP was established. These were also compared with a native PAGE. In SDS-PAGE, bovine type I collagen showed markings for a triple helix, a double helix and two single strains, α1 and α2. Bovine type II collagen showed markings for a double helix and α1-strains. Human type I collagen showed markings for a triple helix, two double helixes, two α-strains and contaminations. Trials with collagen in Native PAGE did not provide any results. However, the trials with ALP revealed that the different types of ALP had different charge.   Thereafter, blotting was performed. The results showed that all the different types of ALP, besides from E. coli, binds to bovine collagen type I and II and human collagen type I, however within various periods of time. In the trials with collagen coated plates the acquired results showed that some of the different types of ALP bind to collagen. ALP from liver binds the strongest to both collagen type I from rat and type IV from mouse. Intestinal ALP also binds to both types of collagen but not nearly as strong as liver ALP. Serum from rats did bind to collagen type I from rat but not to collagen type IV from mouse. ALP from kidney and human serum did not bind to either types of collagen. The trials concerning the ÄKTApurifier system were executed with ALP from liver alone because it had been proven to bind to bovine type I collagen through the previous methods. The results confirmed that ALP from liver binds to this type of collagen.   The conclusions from this study are that ALP does indeed bind to collagen and does so to the triple helix and double helix form as well as the single strains of collagen. In other words the part of the structure in collagen that ALP binds to must exist in all three stages of collagen formation. Furthermore, it seems like some of the different types of ALP has a higher affinity for binding to collagen, as the time for binding to collagen varies for the different types of ALP. The results differed between methods concerning different types of ALP. Although, the method we consider to give the best result was blotting. However, the method using ÄKTApurifier can be complementary but needs further development.

In this research, a method for site-selective attachment of synthetic molecules into glycoproteins using Boronic acid (BA)-directed tosyl chemistry is proposed. The synthetic BA-tosyl chemical probes are composed of boronic asid as a affinity ligand, a tosyl group as a reactive group and a terminal alkyne group for reporting. In neutral and alkaline environment, boronic acid can act as a targeting head to react with the cis-diol of carbohydrates and therefore forms a covalently reversible boronic diester ring. The newly formed boronate ring can withdraw the probe moeular close to the molecular surface of glycoproteins of interest. Followed by a SN2 reaction with the nucleophilic residues of labeled glycoproteins, the report alkyne group can covalently shift to the protein surface apart from the BA-tosyl skeleton. With the competition of polyols, the BA modified carbohydrates can be recovered to the native glycan structures. The traceless labeling strategy developed in the work has been demonstrated in the specific interaction with a known glycoprotein feutin with negatives controls. We believe that the successful development of this methodology can certainly accelerate the study of glycoproteomics and glycobiology.

Arginine vasopressin (AVP) is a hypothalamic nonapeptide which regulates the hypothalamic-pituitary-adrenal axis response to stress by stimulating the secretion of adrenocorticotropin (ACTH) from corticotroph cells of the anterior pituitary. This effect is mediated by binding of AVP to the pituitary vasopressin receptor (V1bR). The V1bR belongs to the G protein-coupled receptor (GPCR) super family. Repeated stimulation of anterior pituitary cells with AVP has been shown to produce a loss of responsiveness to subsequent AVP stimulation. This phenomenon appears to be mediated by desensitisation of the V1bR, and may be due to phosphorylation of the receptor by G protein-coupled receptor kinase 5 (GRK5). The aim of this research was to establish and validate methods that would allow the role of GRK5 in the desensitisation of V1bR to AVP stimulation to be investigated. As no isoform specific inhibitors for GRK5 were available, HEK293 cells transiently transfected with the rat V1bR were used as a model system for this research. This allowed RNA interference (RNAi) to be used to knockdown GRK5 expression. The protocol for RNAi-mediated knockdown of GRK5 was established as part of this research. Protocols for Western blotting and qRT-PCR were also established to allow the RNAi-mediated knockdown of GRK5 protein and mRNA to be measured. Transfection of HEK293 cells with 10nM GRK5-targeting small interfering RNAs (siRNAs) reduced the expression of GRK5 protein to 53.4% ± 3.4% (mean ± SEM) of that seen in untreated control cells at 84 hours after transfection, while GRK5 mRNA levels were reduced to 28.7% ± 1.9% (mean ± SEM) of that of control cells 48 hours after transfection. An experimental protocol was designed in this research that would coordinate the RNAi-mediated knockdown of GRK5 with transient transfection of the HEK293 cells with the rV1bR. Since, activated V1bRs couple to Gq/11 and stimulate the production of inositol phosphates (IPs), the responsiveness of the V1bR can be determined by measuring the accumulation of [H³]-IPs in cells labelled with [H³]-myo-inositol. In the protocol designed, the effect of GRK5 knockdown on V1bR desensitisation is determined by stimulating HEK293 cells expressing the rV1bR (and previously transfected with GRK5-targeting siRNA) with 0nM or 100nM AVP for 0, 5, 15, 30 or 60 minutes, and comparing the accumulation if IPs over time with that of cells that are not transfected with GRK5-targeting siRNA. This protocol can be used in future to investigate the role of GRK5 in V1bR desensitisation, and may be adapted to determine if other GRK isoforms are involved in V1bR desensitisation.

Arylamine N-acetyltransferases (NATs) were partially purified from human breast tumor tissues with complete separation of the isoforms in DEAE-Cellulose ion-exchange step. NAT with activity towards p-aminobenzoic acid (PABA) was isolated and purified from human breast tumor with 77 % yield and a purification factor of 5-fold. NAT with activity towards sulfamethazine (SMZ) was isolated and purified from human breast tumor with 21 % yield and a purification factor of 3-fold. Further purification attempts by Blue Sepharose affinity column chromatography resulted in the complete loss of both enzyme activities. The NAT1 purified from human breast tumor tissues had a molecular weight (Mr) value of about 27600 and an isoelectric point (pI) around 4.8, as confirmed by SDS-PAGE, IEF and Western blotting analysis. With immunohistochemical analysis, level of intensity of NAT1 immunostaining was observed to be going from weak in reduction mammoplasty samples to strongest in malignant breast tissue. The interindividual variation in the conjugation of p-aminobenzoic acid (PABA) and of sulfamethazine (SMZ) by cytosolic arylamine N-acetyltransferases (NATs) were investigated in 30 human breast tumor and matched samples. The average specific activity against PABA was calculated as 13&amp / #61617 / 2 pmole/min/mg protein for breast control NATs, and 20&amp / #61617 / 3 pmole/min/mg protein for breast tumor NATs. The average specific activity against SMZ was calculated as 12&amp / #61617 / 2 pmole/min/mg protein for breast control NATs, and 34&amp / #61617 / 6 pmole/min/mg protein for breast tumor NATs. Wilcoxon test revealed that the difference between the control and tumor groups is statistically significant with respect to the NAT1 activities as well as NAT2 activities. In three (3/30, 10%) patients tumor and tumor-free breast tissue NAT1 activity was not detectable. Among control tissues, the percentage of measurable NAT2 activity was 77% (23/30), while in tumor tissues it increased to 91%. Chemotherapy treatment was observed to have a slight inhibitory effect on mean NAT1 and NAT2 activities. There was an indication of a possible negative association with mean NAT1 activity and estrogen receptor status, while mean tumor NAT2 activity was observed to increase among estrogen receptor positive patients. Grade of malignancy seems to be positively associated with NAT1, but no such association could be suggested for NAT2 enzyme. Menopausal state of the patient was suggested to have a significant effect on NAT2 activity. Genotype determination of NATs revealed that NAT1*4 and NAT2*5A allele being most common among 10 breast cancer patients. NAT1*11 allele was prevalent among postmenopausal women. The putative rapid NAT1 genotypes was found to display lower control and tumor mean NAT1 activities compared to normal NAT1 genotypes. Among slow NAT2 acetylators, mean tumor NAT2 activities was found to be significantly higher than respective controls.

High quality reagents are preconditions for high performance protein analyses. But despite progress in some techniques, e.g. mass spectrometry, there is still a lack of affinity-based detection techniques with enhanced precision, specificity, and sensitivity. Building on the concept of multiple affinity recognition reactions and signal amplification, a proximity ligation assay (PLA) was developed as a molecular tool for analyzing proteins and their post-translational modification and interactions. PLA enhanced the analysis of protein expression levels and post-translational modifications in western blotting (Paper I), which had elevated sensitivity and specificity, and an ability to investigate protein phosphorylation. A general and straightforward method was established for the functionalization of affinity reagents through adding DNA strands to protein domains for protein analysis in medicine (Paper II). A method for protein domain-mediated conjugation was developed to simplify the use of recombinant affinity reagents, such as designed ankyrin repeat protein (DARPin), in DNA-mediated protein analyses. Alzheimer’s disease (AD) is characterized by progressive cognitive decline and memory impairment, and amyloid-beta plaques and neurofibrillary tangles (NFT) in the brain are clinical hallmarks of the disease. In order to understand the mechanisms underlying the formation of NFT, in situ PLA was used to explore the role of microtubule affinity related kinase 2 (MARK2) in phosphorylating tau protein during the pathological progress of AD (Paper III). The analyses of roles of MARK proteins 1-4 in phosphorylating tau protein in cells and in post-mortem human brains were performed in Paper IV. The focus of this thesis was the study of post-translational modifications and interactions of proteins in medicine. Procedures for high performance protein analysis in western blotting via proximity ligation were developed, and a functionalization method for recombinant affinity reagents in DNA-mediated protein analysis was established. These and other techniques were used to investigate the roles of tau-phosphorylating MARK family proteins in AD.

Thesis (M.Sc. (Biotechnology))--Mahidol University, 2007. / LICL has E-Thesis 0023 ; please contact computer services.